RECRUITING

Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV

Talk to us

Conditions

MonkeypoxHIV InfectionsAIDS

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to examine the extent of mpox viral spread and immunologic markers in people with advanced HIV. Study findings will enhance knowledge of mpox pathogenesis in severely immunocompromised people, which can inform treatment and prevention of severe illness and deaths associated with mpox in people with advanced HIV.

Official Title

Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV

Quick Facts

Study Start:2023-03-17
Study Completion:2024-10-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06045923

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age ≥18 years; AND
  2. * HIV infection with CD4 count \< 200 cells/uL; AND
  3. * Probable or confirmed mpox (does NOT need to be a new diagnosis); AND
  4. * Hospitalized while symptomatic from mpox, for reasons other than (or in addition to) infection prevention and control
  1. * Inability of the individual or appropriate proxy to provide informed consent.
  2. * In the judgment of the clinical treating team, has a medical condition or other factor that might affect their ability to participate in the evaluation.

Contacts and Locations

Study Contact

Faisal Minhaj, Pharm.D.
CONTACT
678-642-1093
poxvirus@cdc.gov

Principal Investigator

Agam Rao, MD
PRINCIPAL_INVESTIGATOR
Centers for Disease Control and Prevention
Irini Sereti, MD
STUDY_DIRECTOR
National Institutes of Health (NIH)
Faisal Minhaj, Pharm.D.
STUDY_DIRECTOR
Centers for Disease Control and Prevention
Shama Cash-Goldwasser, MD
STUDY_DIRECTOR
Centers for Disease Control and Prevention
Jesse OShea, MD
STUDY_DIRECTOR
Centers for Disease Control and Prevention
Christine Hughes, PhD
STUDY_DIRECTOR
Centers for Disease Control and Prevention
Brian Epling, MD
STUDY_DIRECTOR
National Institutes of Health (NIH)
Katy Saliba, PhD
STUDY_DIRECTOR
National Institutes of Health (NIH)
Jason Zucker, MD
STUDY_DIRECTOR
Columbia University
Sarah Reagan Steiner, MD
STUDY_DIRECTOR
Centers for Disease Control and Prevention
Sarah Park, MD
STUDY_DIRECTOR
Karius Laboratories

Study Locations (Sites)

Centers for Disease Control and Prevention
Atlanta, Georgia, 30333
United States

Collaborators and Investigators

Sponsor: Centers for Disease Control and Prevention

  • Agam Rao, MD, PRINCIPAL_INVESTIGATOR, Centers for Disease Control and Prevention
  • Irini Sereti, MD, STUDY_DIRECTOR, National Institutes of Health (NIH)
  • Faisal Minhaj, Pharm.D., STUDY_DIRECTOR, Centers for Disease Control and Prevention
  • Shama Cash-Goldwasser, MD, STUDY_DIRECTOR, Centers for Disease Control and Prevention
  • Jesse OShea, MD, STUDY_DIRECTOR, Centers for Disease Control and Prevention
  • Christine Hughes, PhD, STUDY_DIRECTOR, Centers for Disease Control and Prevention
  • Brian Epling, MD, STUDY_DIRECTOR, National Institutes of Health (NIH)
  • Katy Saliba, PhD, STUDY_DIRECTOR, National Institutes of Health (NIH)
  • Jason Zucker, MD, STUDY_DIRECTOR, Columbia University
  • Sarah Reagan Steiner, MD, STUDY_DIRECTOR, Centers for Disease Control and Prevention
  • Sarah Park, MD, STUDY_DIRECTOR, Karius Laboratories

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-17
Study Completion Date2024-10-01

Study Record Updates

Study Start Date2023-03-17
Study Completion Date2024-10-01

Terms related to this study

Additional Relevant MeSH Terms

  • Monkeypox
  • HIV Infections
  • AIDS